The Joint Corp.
NASDAQ:JYNTMedical - Care Facilities
+$0.17 today
- Market cap
- $91.03M
- Beta
- 1.10
- P/E (TTM)
- 40.7
- EPS (TTM)
- $0.23
Volume 0.05M
Average 0.07M
JYNT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
The Joint Corp.NASDAQ: JYNT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How JYNT compares with its peers on the latest reported figures
- JYNT's LTM Mar 2026 research & development of $0 is the 10th highest of the 11 companies compared; the peer median is $10.22M.
- Research & development amounts to 0.0% of revenue for JYNT, versus a peer median of 22.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $30.12M | +20.6% | +35.3% | — | |
| LTM Mar 2026 | $13.63M | +6.1% | +36.1% | 4.5% | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $7.56M | +84.3% | +13.2% | 6.1% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
| LTM Mar 2026 | $319.38K | -20.4% | -50.4% | 80.5% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding JYNT) | $10.22M | -7.8% | +7.0% | 22.4% | |
Competitors are the stored peer set for JYNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 80.01M | 101.25M | 46.98M | 52.16M | 54.9M |
| Cost of Revenue | 7.67M | 9.17M | 10.48M | 11.52M | 11.23M |
| Gross Profit | 72.35M | 92.08M | 36.5M | 40.65M | 43.67M |
| Gross Margin | 90.4% | 90.9% | 77.7% | 77.9% | 79.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 62.27M | 81.95M | 34.92M | 41.1M | 42.93M |
| Operating Expenses | 66.22M | 91.25M | 36.18M | 42.54M | 44.58M |
| Depreciation & Amortization | 3.92M | 6.65M | 8.58M | 4.72M | 1.71M |
| EBITDA | 10.07M | 7.89M | 8.88M | 2.9M | 1.48M |
| EBITDA Margin | 12.6% | 7.8% | 18.9% | 5.6% | 2.7% |
| Operating Income | 6.13M | 828.25K | 318.3K | (1.89M) | (905.48K) |
| Operating Margin | 7.7% | 0.8% | 0.7% | -3.6% | -1.6% |
| Interest Income | 0 | 133.1K | 0 | 280.29K | 0 |
| Interest Expense | 0 | 953.53K | 64.29K | 0 | 0 |
| Other Income / Expenses | (69.88K) | (133.1K) | (64.29K) | 280.29K | 675.97K |
| Income Before Tax | 6.06M | 695.15K | 254.01K | (1.61M) | (229.5K) |
| Pre-Tax Margin | 7.6% | 0.7% | 0.5% | -3.1% | -0.4% |
| Income Tax Expense | (1.51M) | 68.45K | 11.02M | 5.61K | 38.65K |
| Net Income | 7.57M | 626.71K | (9.75M) | (5.8M) | 2.91M |
| Net Margin | 9.5% | 0.6% | -20.8% | -11.1% | 5.3% |
| EPS (Basic) | 0.46 | 0.04 | (0.66) | (0.39) | 0.19 |
| EPS (Diluted) | 0.44 | 0.04 | (0.66) | (0.39) | 0.19 |
| Weighted Avg Shares | 14.32M | 14.49M | 14.69M | 14.92M | 15.13M |
| Weighted Avg Shares (Diluted) | 14.94M | 14.87M | 14.69M | 15.15M | 15.13M |
The Joint Corp.
NASDAQ:JYNT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.